0JDB Stock Overview A medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Invitae Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for Invitae Historical stock prices Current Share Price US$0.0005 52 Week High US$1.25 52 Week Low US$0.0001 Beta 2.8 1 Month Change 0% 3 Month Change -50.00% 1 Year Change -99.96% 3 Year Change -100.00% 5 Year Change -100.00% Change since IPO -99.99%
Recent News & Updates
Invitae Launches Unlock Behind the Seizure Program for Pediatric Epilepsy Patients Jul 22 First Amended Disclosure Statement Approved for Invitae Corporation Jun 15
Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million. Apr 26
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance Apr 11
Invitae Launches Update to Invitae Generation: Clinical Variant Modeling Improves Variant Classification Mar 12
Invitae Corporation Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023 Mar 06 See more updates
Invitae Launches Unlock Behind the Seizure Program for Pediatric Epilepsy Patients Jul 22 First Amended Disclosure Statement Approved for Invitae Corporation Jun 15
Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million. Apr 26
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance Apr 11
Invitae Launches Update to Invitae Generation: Clinical Variant Modeling Improves Variant Classification Mar 12
Invitae Corporation Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023 Mar 06 Invitae Corporation Filed for Bankruptcy Motion for Joint Administration Filed by Invitae Corporation Invitae Corporation(OTCPK:NVTA) dropped from S&P TMI Index The New York Stock Exchange to Commence Delisting Proceedings against Invitae Feb 07
Invitae Corporation May File for Bankruptcy Feb 06
New minor risk - Market cap size Feb 06
Invitae Corporation Announces Board Changes Dec 12
Invitae Corporation Announces the Retirement of Robert L. Nussbaum as Chief Medical Officer, Effective December 29, 2023 Nov 18
Invitae Corporation Appoints Ana J. Schrank as Chief Accounting Officer Nov 17
New major risk - Financial position Nov 12
Invitae Corporation Reaffirms Earnings Guidance for the Full Year 2023 Nov 10
Third quarter 2023 earnings released: US$3.42 loss per share (vs US$1.27 loss in 3Q 2022) Nov 09
Invitae Corporation to Report Q3, 2023 Results on Nov 08, 2023 Nov 02
Invitae Corporation Announces Findings from the Study to Date on Uncertain Results from Hereditary Disease Genetic Testing Oct 26
Invitae Corporation Appoints David Sholehvar as Chief Operating Officer, Effective November 13, 2023 Oct 20
Invitae Announces Results of Its Collaborative Study on Universal Hereditary Cancer Genetic Testing in All Patients with Breast Cancer in A Rural Population in the Annals of Surgical Oncology Oct 13
Invitae Corporation Announces Change of Chief Financial Officer, Effective October 2, 2023 Sep 28 Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard Sep 23
New major risk - Financial position Sep 19 Invitae Corporation Announces Clinical Trial Results Support Genetic Testing of All Patients with Prostate Cancer
Invitae Corporation Provides Revenue Guidance for the Year 2023 Aug 11
Invitae Corporation Provides Revenue Guidance for the Year 2023 Aug 10
Second quarter 2023 earnings released: US$0.78 loss per share (vs US$10.87 loss in 2Q 2022) Aug 09 Invitae Corporation to Report Q2, 2023 Results on Aug 08, 2023 Jul 28
Invitae Corporation Announces Executive Changes
Invitae Corporation Announces Nine Studies to Be Presented At the 2023 American Society of Clinical Oncology Annual Meeting Reinforce the Critical Role of Germline Genetic Testing in Oncology May 27
Invitae Announces CFO Changes May 26
President recently sold US$54k worth of stock May 21
Invitae Corporation Announces It Intends to Appeal the Verdict Delivered by A Jury At the United States District Court May 17
First quarter 2023 earnings released: US$0.77 loss per share (vs US$0.80 loss in 1Q 2022) May 10
Full year 2022 earnings released: US$13.18 loss per share (vs US$1.80 loss in FY 2021) Mar 01
Invitae Corporation to Report Q4, 2022 Results on Feb 28, 2023 Feb 15
Invitae Corporation Appoints William H. Osborne to its Board of Directors Jan 31
Director recently sold US$115k worth of stock Dec 24
Invitae Releases Data Use Transparency Report, Demonstrating the Impact of Patient Data on Genetic Research Dec 08
Invitae Launches Rare Patient Network for Pediatric Patients with Rare Neurodevelopmental Diseases Dec 02
Third quarter 2022 earnings released: US$1.27 loss per share (vs US$0.91 loss in 3Q 2021) Nov 10
Invitae Corporation Reiterates Earnings Guidance for the Year 2022 Nov 10
Invitae Corporation Reports Asset Impairments for the Third Quarter Ended September 30, 2022 Nov 09
Invitae Corporation Study Shows Therapy Informed by Genetic Testing Reduces Seizures in Some Patients with Epilepsy Nov 01
Invitae Corporation to Report Q3, 2022 Results on Nov 08, 2022 Oct 26
Invitae Corporation Reiterates Revenue Guidance for the Year 2022 Aug 10
Invitae Corporation to Report Q2, 2022 Results on Aug 09, 2022 Aug 03 Invitae Announces Strategic Business Realignment to Accelerate Its Path to Positive Cash Flow Invitae Corporation Announces Executive Leadership and Board Changes
Chief Operating Officer recently sold US$108k worth of stock May 21
Invitae Corporation Launches Expanded Pharmacogenomics Panel and Specialized Mental Health Panel May 20
First quarter 2022 earnings released: US$0.80 loss per share (vs US$0.56 loss in 1Q 2021) May 04
Invitae Corporation, Annual General Meeting, Jun 06, 2022 Apr 23
Invitae Corporation, Annual General Meeting, Jun 06, 2022 Apr 22
Invitae Corporation to Report Q1, 2022 Results on May 03, 2022 Apr 21
Invitae Introduces First Comprehensive Genetic Test Suite for Neurodevelopmental Disorders Apr 05
Invitae Announces the Launch of Invitae Digital Health Mar 30
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 26
Invitae Corporation Provides Revenue Guidance for 2022 Feb 25
Invitae Corporation to Report Q4, 2021 Results on Feb 24, 2022 Feb 11
Third quarter 2021 earnings released: US$0.91 loss per share (vs US$0.78 loss in 3Q 2020) Nov 09
Invitae Corporation (NYSE:NVTA) entered into definitive agreement to acquire Ciitizen Corporation from group of investors for approximately $350 million. Sep 08
Chief Medical Officer recently sold US$540k worth of stock Aug 20
Exact Sciences Approaches Invitae Aug 10
Second quarter 2021 earnings released: US$0.64 loss per share (vs US$1.29 loss in 2Q 2020) Aug 05
Director Jason Myers has left the company Jul 13
Chief Financial Officer Shelly Guyer has left the company Jun 24 Shareholder Returns 0JDB GB Healthcare GB Market 7D 0% 0.9% 2.0% 1Y -100.0% -20.5% 10.8%
See full shareholder returns
Return vs Market: 0JDB underperformed the UK Market which returned 6.6% over the past year.
Price Volatility Is 0JDB's price volatile compared to industry and market? 0JDB volatility 0JDB Average Weekly Movement n/a Healthcare Industry Average Movement 6.4% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.8% 10% least volatile stocks in GB Market 2.7%
Stable Share Price: 0JDB's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0JDB's volatility change over the past year.
About the Company Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners.
Show more Invitae Corporation Fundamentals Summary How do Invitae's earnings and revenue compare to its market cap? 0JDB fundamental statistics Market cap US$114.60k Earnings (TTM ) -US$1.44b Revenue (TTM ) US$481.58m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0JDB income statement (TTM ) Revenue US$481.58m Cost of Revenue US$350.95m Gross Profit US$130.64m Other Expenses US$1.57b Earnings -US$1.44b
Last Reported Earnings
Sep 30, 2023
Earnings per share (EPS) -5.03 Gross Margin 27.13% Net Profit Margin -299.14% Debt/Equity Ratio -124.7%
How did 0JDB perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/08/05 17:10 End of Day Share Price 2024/05/17 00:00 Earnings 2023/09/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Invitae Corporation is covered by 14 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Raymond Myers Benchmark Company Steven Wardell Chardan Capital Markets, LLC Daniel Leonard Credit Suisse
Show 11 more analysts 
